Initially tested in a phase I trial (NCT02157051) involving patients with advanced-stage, HER2-negative breast cancer, STEMVAC demonstrated safety and immunogenicity, especially in eliciting T-cell responses against non-traditional tumor-associated targets. Here, ERBB2 is linked to breast carcinoma.